Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following application to register a trade name product under section 9(1) of the Act:

Trade Name: TURBO Advance + Fluke

Reference: A012164

Active Ingredients and Concentrations:

2g/L Eprinomectin, 80g/L Levamisole HCL plus 120g/L Triclabendazole with 1g/L Selenium and 4.4g/L Cobalt

Formulation Type: Aqueous Suspension

Application method/administration route:

Oral Drench; 1mL/10kg body weight by mouth delivering 0.2mg/kg Eprinomectin, 8mg/kg Levamisole HCl, 12mg/kg Triclabendazole, 0.1mg/kg Selenium and 0.44mg/kg Cobalt.

Use Claim:

For the treatment and control of internal parasites in cattle. Also provides a supplemental source of selenium and cobalt

Other Information:

For the effective treatment and control of susceptible strains of the following species of parasites:

Gastrointestinal nematodes: For the treatment and control of the following mature and immature gastrointestinal parasites (*includes inhibited fourth stage larvae):

Barbers pole worm (Haemonchus placei), Stomach hair worm (Trichostrongylus axei), Small brown stomach worm* (Ostertagia ostertagi), Small intestinal worm (Cooperia oncophora), Thread-necked intestinal worms (Nematodirus helvetianus, Nematodirus spathiger), Intestinal threadworm (Strongyloides papillosus), Cattle hookworm (Bunostomum phlebotomum), Nodule worm (Oesophagostomum radiatum), Large-mouthed bowel worm – adults (Chabertia spp.), Whipworm – adults (Trichuris spp.).

Lungworm: Dictyocaulus viviparus.

Liver fluke: Fasciola hepatica, early immature, immature and mature stages.

Anthelmintic resistant strains: TURBO Advance + Fluke is effective against parasite strains susceptible to eprinomectin and/or levamisole. It is effective against strains that are resistant to the avermectin/milbemycin action family (including resistant strains of Cooperia oncophora) or benzimidazole or imidazothiazole (levamisole/morantel) anthelmintic families, or are resistant to combinations of a benzimidazole and avermectin/milbemycin, or a benzimidazole and imidazothiazole anthelmintic.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

1. must state in full the reasons for making the submission;
2. may state any decision sought on that application; and
3. must be received by the director-general no later than 30 working days after the date of this notice.

Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.

The following address is:

1. where submissions on this application are to be sent;
2. where requests for copies of the public information relating to the application can be sent;
3. where public information relating to the application can be viewed; and
4. the director-general’s address for service:

ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.

MPI encourages submission by email.

The applicant’s address for service is:

Alleva Animal Health Limited, 1/116a Harris Road, East Tamaki, Auckland 2013. Postal Address: PO Box 34032, Birkenhead, Auckland 0746.

Dated at Wellington this 26th day of February 2025.

SHALEEN NARAYAN, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).